{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:44:36Z","timestamp":1792586676652,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase inhibitors (JAKi) are increasingly being used in the management of autoimmune diseases across rheumatology, gastroenterology, and dermatology, including in women of childbearing age. Consequently, pregnancies occurring during JAKi treatment are becoming more common. However, uncertainties regarding their safety during pregnancy remain, and current human data are insufficient to allow a comprehensive assessment of fetal risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational data of pregnancies with first trimester JAKi exposure, recorded in the German Embryotox database, was analyzed. Pregnancies were prospectively enrolled between January 1, 2017, and November 15, 2025. Study endpoints included major congenital anomalies, pregnancy loss, and neonatal parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort comprised a total of 44 pregnancies exposed to baricitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917), filgotinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), tofacitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), or upadacitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916). A total of 32 live births were recorded. Among these, two major congenital anomalies were observed, one ventricular septal defect and one hypospadias. Five spontaneous abortions occurred, including one case of fetal anencephaly, and seven elective terminations of pregnancy were reported. Additional neonatal assessments revealed two preterm births at 36\u2009weeks\u2019 gestation, three infants born small for gestational age, and two newborns large for gestational age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current evidence is insufficient to establish or exclude an association between JAK inhibitor exposure and adverse fetal outcomes. To date, the potential for harmful effects cannot be ruled out due to the limited available data. Therefore, routine use of JAKi during pregnancy is not recommended and treatment should be approached with caution, and requires a critical risk-benefit assessment until further data is obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The study was retrospectively registered in the German Clinical Trials Register on March 16, 2026 (DRKS00039622).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-026-01263-4","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:45:51Z","timestamp":1792485951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pregnancy outcome after first-trimester exposure to JAK inhibitors - an evaluation of the German Embryotox cohort"],"prefix":"10.1186","volume":"27","author":[{"given":"Anna-Sophia","family":"Habbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Dathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"5","key":"1263_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.25259\/IJDVL_8_2023","volume":"89","author":"SP Raychaudhuri","year":"2023","unstructured":"Raychaudhuri SP, Raychaudhuri SK. JAK inhibitor: introduction. Indian J Dermatol Venereol Leprol. 2023;89(5):688\u201390. https:\/\/doi.org\/10.25259\/IJDVL_8_2023.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"1263_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"1263_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3238\/arztebl.m2021.0353","volume":"119","author":"WM Merz","year":"2022","unstructured":"Merz WM, Fischer-Betz R, Hellwig K, Lamprecht G, Gembruch U. Pregnancy and autoimmune disease. Dtsch Arztebl Int. 2022;119(9):145\u201356. https:\/\/doi.org\/10.3238\/arztebl.m2021.0353.","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"1263_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen A, Spinelli FR, Telliez JB, O\u2019shea JJ, Silvennoinen O, Gadina M. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20(10):649\u201365. https:\/\/doi.org\/10.1038\/s41584-024-01153-1.","journal-title":"Nat Rev Rheumatol"},{"key":"1263_CR5","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. https:\/\/doi.org\/10.1016\/j.intimp.2020.106210.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1263_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1263_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41573-025-01336-9","volume":"25","author":"T Haikarainen","year":"2026","unstructured":"Haikarainen T, Virtanen AT, Cravatt BF, Silvennoinen O. Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications. Nat Rev Drug Discov. 2026;25(4):268\u201389. https:\/\/doi.org\/10.1038\/s41573-025-01336-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1263_CR8","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s10067-024-07142-9","volume":"43","author":"K Anjiki","year":"2024","unstructured":"Anjiki K, Hayashi S, Ikuta K, Suda Y, Kamenaga T, Tsubosaka M, et al. JAK inhibitors inhibit angiogenesis by reducing VEGF production from rheumatoid arthritis-derived fibroblast-like synoviocytes. Clin Rheumatol. 2024;43(11):3525\u201336. https:\/\/doi.org\/10.1007\/s10067-024-07142-9.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1263_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019shea","year":"2015","unstructured":"O\u2019shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66(1):311\u201328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537.","journal-title":"Annu Rev Med"},{"key":"1263_CR10","doi-asserted-by":"crossref","unstructured":"Quotti Tubi L, Canovas Nunes S, Mandato E, Pizzi M, Vitulo N, M D, et al. CK2beta regulates hematopoietic stem cell biology and Erythropoiesis. Hemasphere. 2023;7(12):e978.","DOI":"10.1097\/HS9.0000000000000978"},{"issue":"1","key":"1263_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13075-021-02587-8","volume":"23","author":"P Di Benedetto","year":"2021","unstructured":"Di Benedetto P, Ruscitti P, Berardicurti O, Panzera N, Grazia N, Vito Nolfi M D, et al. Blocking Jak\/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. Arthritis Res Ther. 2021;23(1):213.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1263_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/ibd\/izaf027","volume":"31","author":"S Ehrlich","year":"2025","unstructured":"Ehrlich S, Long M, Kane S, Mahadevan U. Placental transfer of upadacitinib among pregnant women with inflammatory bowel disease. Inflamm Bowel Dis. 2025;31(5):1489\u201391. https:\/\/doi.org\/10.1093\/ibd\/izaf027.","journal-title":"Inflamm Bowel Dis"},{"key":"1263_CR13","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.crtox.2024.100149","volume":"6","author":"GAM Eliesen","year":"2024","unstructured":"Eliesen GAM, Fransen M, van Hove H, van den Broek PHH, Greupink R. Placental transfer of tofacitinib in the ex vivo dual-side human placenta perfusion model. Curr Res Toxicol. 2024;6:100149. https:\/\/doi.org\/10.1016\/j.crtox.2024.100149.","journal-title":"Curr Res Toxicol"},{"issue":"4","key":"1263_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cgh.2025.06.007","volume":"24","author":"D Duricova","year":"2025","unstructured":"Duricova D, Sonnenberg E, Augustijns P, Mitrova K, Anderson PO, Julsgaard M. Upadacitinib in mothers with inflammatory bowel disease: placental transfer and breast milk excretion. Clin Gastroenterol Hepatol. 2025;24(4):24. https:\/\/doi.org\/10.1016\/j.cgh.2025.06.007.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1263_CR15","unstructured":"European Medicines Agency. Olumiant (baricitinib): package leaflet: information for the patient. 2026. Accessed Oct15, 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant."},{"key":"1263_CR16","unstructured":"European Medicines Agency. Jyseleca (filgotinib): package leaflet: information for the patient. 2025. Accessed Oct15, 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jyseleca."},{"key":"1263_CR17","unstructured":"European Medicines Agency. Xeljanz (tofacitinib): package leaflet: information for the patient. 2026. Accessed Oct 15, 2026 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz."},{"key":"1263_CR18","unstructured":"European Medicines Agency. Rinvoq (upadacitinib): package leaflet: information for the patient. 2026. Accessed Oct 15, 2026 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq."},{"key":"1263_CR19","doi-asserted-by":"publisher","unstructured":"Julsgaard M, Baunwall SM, Seow C, Duricova D, Kane S, Zacharias N, et al. DOP041 pregnancy and infant outcomes after in utero exposure to JAK inhibitors in inflammatory bowel disease: a global multicenter cohort study. J Crohn\u2019s Colitis. 2026, 20;(Supplement_1). https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf231.078.","DOI":"10.1093\/ecco-jcc\/jjaf231.078"},{"issue":"1","key":"1263_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cgh.2024.01.019","volume":"23","author":"K Mitrova","year":"2025","unstructured":"Mitrova K, Julsgaard M, Augustijns P, Cerna K, Mahadevan U, Duricova D. Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations. Clin Gastroenterol Hepatol. 2025;23(1):163\u20135.e163.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1263_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40261-024-01353-3","volume":"44","author":"M Chaparro","year":"2024","unstructured":"Chaparro M, Ceballos D, Vicente R, Gisbert JP. Experience of Tofacitinib Use in pregnancy in patients with ulcerative colitis. Clin Drug Invest. 2024;44(4):285\u201388. https:\/\/doi.org\/10.1007\/s40261-024-01353-3.","journal-title":"Clin Drug Invest"},{"key":"1263_CR22","doi-asserted-by":"publisher","unstructured":"Costanzo G, Firinu D, Losa F, Deidda M, Barca MP, Del Giacco S. Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther. 2020;12:1759720X19899296. https:\/\/doi.org\/10.1177\/1759720X19899296.","DOI":"10.1177\/1759720X19899296"},{"issue":"8","key":"1263_CR23","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/jpen.70009","volume":"49","author":"D Coman","year":"2025","unstructured":"Coman D, Orlicka K, Daoud DC. Successful pregnancy in a patient with active Crohn\u2019s disease, chronic intestinal failure, and long-term parenteral nutrition receiving upadacitinib: a case report. JPEN J Parenter Enter nutr. 2025;49(8):1028\u201331. https:\/\/doi.org\/10.1002\/jpen.70009.","journal-title":"JPEN J Parenter Enter nutr"},{"issue":"1","key":"1263_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ibd\/izae146","volume":"31","author":"SA Urquhart","year":"2025","unstructured":"Urquhart SA, Chedid VG, Kane SV. Use of Upadacitinib as salvage therapy for ulcerative colitis in pregnancy: a case report. Inflamm Bowel Dis. 2025;31(1):300\u201301. https:\/\/doi.org\/10.1093\/ibd\/izae146.","journal-title":"Inflamm Bowel Dis"},{"key":"1263_CR25","doi-asserted-by":"publisher","unstructured":"Gargiulo L, Ibba L, Fiorillo G, Valenti M, Sierzputowska P, Costanzo A, et al. Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;38(3). https:\/\/doi.org\/10.1111\/jdv.19557.","DOI":"10.1111\/jdv.19557"},{"key":"1263_CR26","doi-asserted-by":"publisher","unstructured":"Geeganage G, Flynn DJ, Martinez S, Wang MJ, Spiel M, Rabinowitz LG, et al. Upadacitinib as rescue therapy in a pregnant patient with IBD. ACG case rep 2025. ACG Case Rep J. 2025;12(5):e01701. https:\/\/doi.org\/10.14309\/crj.0000000000001701.","DOI":"10.14309\/crj.0000000000001701"},{"key":"1263_CR27","doi-asserted-by":"publisher","unstructured":"Arzivian A, Zhang E, Laube R, Leong R. First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review. Clin Case Rep. 2024;12(4):e 8764. https:\/\/doi.org\/10.1002\/ccr3.8764.","DOI":"10.1002\/ccr3.8764"},{"key":"1263_CR28","doi-asserted-by":"crossref","unstructured":"Ernest-Suarez K, Murguia-Favela LE, Novak KL, Panaccione R, Constantinescu C, Seow CH. Normal infant immunologic assessment and uneventful live rotavirus vaccination despite continuous tofacitinib exposure in utero and during breastfeeding. Crohns Colitis. 2024;360, 6(1):otae006.","DOI":"10.1093\/crocol\/otae006"},{"issue":"17","key":"1263_CR29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/bdr2.1942","volume":"113","author":"M Fernandez-Sanchez","year":"2021","unstructured":"Fernandez-Sanchez M, Ribes-Artero H, Roma-Sanchez E, Gomez-Portero MR, Guerrero-Hurtado E, Garcia-Pellicer J, et al. Fetal exposure to tofacitinib during the first trimester: a healthy newborn case report. Birth Defects Res. 2021;113(17):1275\u201379. https:\/\/doi.org\/10.1002\/bdr2.1942.","journal-title":"Birth Defects Res"},{"issue":"4","key":"1263_CR30","doi-asserted-by":"publisher","first-page":"04","DOI":"10.1093\/ecco-jcc\/jjaf049","volume":"19","author":"K Mitrova","year":"2025","unstructured":"Mitrova K, Kostrejova M, Zdychyncova K, Lukas M, Duricova D. Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child. J Crohns Colitis. 2025;19(4):04. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf049.","journal-title":"J Crohns Colitis"},{"key":"1263_CR31","doi-asserted-by":"publisher","unstructured":"Ogbutor C, Chen LC, Kalil LL, Kelley KJ, Craiglow BG, King B, et al. Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series. Int J Womens Dermatol. 2025;11(3):e218. https:\/\/doi.org\/10.1097\/JW9.0000000000000218.","DOI":"10.1097\/JW9.0000000000000218"},{"key":"1263_CR32","doi-asserted-by":"publisher","unstructured":"Zhang C, Shi X, Ding Y, Lin Z, Qian T, Liu X, et al. Pregnancy outcomes following tofacitinib use for synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: case report. Int J Rheum Dis. 2024;27(6):e15209. https:\/\/doi.org\/10.1111\/1756-185X.15209.","DOI":"10.1111\/1756-185X.15209"},{"issue":"5","key":"1263_CR33","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/ibd\/izae076","volume":"30","author":"C Rowan","year":"2024","unstructured":"Rowan C, Yeaman F, Ernest-Suarez K, Martin ML, Panaccione R, Shukla T, et al. Tofacitinib as a rescue therapy for ulcerative colitis in pregnancy. Inflamm Bowel Dis. 2024;30(5):868\u201370. https:\/\/doi.org\/10.1093\/ibd\/izae076.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1263_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/bjd\/ljad279","volume":"189","author":"B Bergamini","year":"2023","unstructured":"Bergamini B, Seneschal J, Meyers KJ, Durand F, Haladyj E, Espinosa G, et al. Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance. Br J Dermatol. 2023;189(6):767\u201369. https:\/\/doi.org\/10.1093\/bjd\/ljad279.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1263_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.14309\/ajg.0000000000003774","volume":"121","author":"U Mahadevan","year":"2025","unstructured":"Mahadevan U, Chaparro M, Segovia M, Guo X, Kulisek N, Wu J, et al. Pregnancy outcomes after maternal or paternal exposure to to facitinib across clinical programs. Am J Gastroenterol. 2025;121(2):549\u201353. https:\/\/doi.org\/10.14309\/ajg.0000000000003774.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1263_CR36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","volume":"47","author":"U Mahadevan","year":"2024","unstructured":"Mahadevan U, Levy G, Gensler L, Ali M, Lacerda AP, Wegrzyn L, et al. Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports. Drug Saf. 2024;47(10):1039\u201349. https:\/\/doi.org\/10.1007\/s40264-024-01454-0.","journal-title":"Drug Saf"},{"issue":"1","key":"1263_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jcm13010034","volume":"13","author":"N Monfared","year":"2023","unstructured":"Monfared N, Gold M, Carbery I, Laube R, Selinger CP. Reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease: a systematic review. J Clin Med. 2023;13(1):20. https:\/\/doi.org\/10.3390\/jcm13010034.","journal-title":"J Clin Med"},{"key":"1263_CR38","unstructured":"Your Child\u2019s medical records\/Kinderuntersuchungsheft. Gemeinsamer Bundesausschuss. 2026. https:\/\/www.g-ba.de\/service\/versicherteninformationen\/untersuchungshefte\/. Accessed July 17, 2026."},{"key":"1263_CR39","unstructured":"EUROCAT Guide 1.5 https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/data-collection\/guidelines-for-data-registration_en#inline-nav-2. Accessed July 17, 2026."},{"key":"1263_CR40","unstructured":"R: a language and environment for statistical computing. https:\/\/www.r-project.org\/. Accessed July 17, 2026."},{"key":"1263_CR41","unstructured":"JRC-EUROCAT Central Registry. Prevalence Data \/ Tables ventricular septal defect 2005-2023. European Commission, joint research Centre (JRC). 2026. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/eurocat-data\/prevalence_en. Accessed March 13, 2026."},{"key":"1263_CR42","unstructured":"Jahresbericht des Bundeslandes Sachsen-Anhalt zur H\u00e4ufigkeit von congenitalen Fehlbildungen und Anomalien sowie genetisch bedingten Erkrankungen 2024. https:\/\/www.angeborene-fehlbildungen.com\/monz_mm\/Dokumente\/Jahresberichte\/Bericht2024_WEB.pdf. Accessed July 14, 2026."},{"issue":"12","key":"1263_CR43","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/S0735-1097(02)01886-7","volume":"39","author":"JI Hoffman","year":"2002","unstructured":"Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890\u2013900.","journal-title":"J Am Coll Cardiol"},{"key":"1263_CR44","unstructured":"Lindsey N, Markwalter V, Michalski A, Pabst L. Prevalence of selcted birth defects from population-based birth defects surveillance programs in the United States, 2018\u20132022 https:\/\/www.cdc.gov\/birth-defects\/media\/pdfs\/2026\/04\/Data-Brief-Birth-Defects-National-Estimates-2018-2022.pdf. Accessed September 9, 2026."},{"key":"1263_CR45","unstructured":"JRC-EUROCAT Central Registry. Prevalence Data \/ Tables hypospadias 2005-2023. European Commission, Joint Research Centre (JRC). 2026. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/eurocat-data\/prevalence_en. Accessed March 13, 2026."},{"issue":"3","key":"1263_CR46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/JU.0000000000004319","volume":"213","author":"TL Leunbach","year":"2025","unstructured":"Leunbach TL, Berglund A, Ernst A, Hvistendahl GM, Rawashdeh YF, Gravholt CH. Prevalence, incidence, and age at diagnosis of Boys with hypospadias: a nationwide population-based epidemiological study. J Urol. 2025;213(3):350\u201360. https:\/\/doi.org\/10.1097\/JU.0000000000004319.","journal-title":"J Urol"},{"key":"1263_CR47","doi-asserted-by":"publisher","unstructured":"Richard MA, Patel J, Benjamin RH, Bircan E, Canon SJ, Marengo LK, et al. Prevalence and clustering of congenital heart defects among boys with hypospadias. JAMA Netw Open. 2022;5(7):e2224152. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.24152.","DOI":"10.1001\/jamanetworkopen.2022.24152"},{"key":"1263_CR48","unstructured":"JRC-EUROCAT Central Registry. Prevalence data \/ tables anencephaly 2005-2023. European commission, Joint Research Centre (JRC). https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/eurocat-data\/prevalence_en 2026. July 14, 2026."},{"key":"1263_CR49","doi-asserted-by":"publisher","unstructured":"Gargiulo L, Ibba L, Fiorillo G, Valenti M, Sierzputowska P, Costanzo A, et al. Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(3):e252\u201353. https:\/\/doi.org\/10.1111\/jdv.19557.","DOI":"10.1111\/jdv.19557"},{"issue":"4","key":"1263_CR50","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/pds.3744","volume":"24","author":"E Wacker","year":"2015","unstructured":"Wacker E, Navarro A, Meister R, Padberg S, Weber-Schoendorfer C, Schaefer C. Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome. Pharmacoepidemiol Drug Saf. 2015;24(4):353\u201360. https:\/\/doi.org\/10.1002\/pds.3744.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10285","key":"1263_CR51","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0140-6736(21)00682-6","volume":"397","author":"S Quenby","year":"2021","unstructured":"Quenby S, Gallos ID, Dhillon-Smith RK, Podesek M, Stephenson MD, Fisher J, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021;397(10285):1658\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(21)00682-6.","journal-title":"Lancet"},{"issue":"1","key":"1263_CR52","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1515\/jpm-2020-0119","volume":"49","author":"M Voigt","year":"2020","unstructured":"Voigt M, Rochow N, Landau-Crangle E, Meyer-Kahrweg LM, Olbertz DM, Kunze M, et al. Individualized sex-specific birth weight percentiles for gestational age based on maternal height and weight. J Perinat Med. 2020;49(1):94\u2013103.","journal-title":"J Perinat Med"},{"key":"1263_CR53","doi-asserted-by":"publisher","unstructured":"Abolhassani N, Noseda R, Dao K, Girardin FR, Bedussi F, Ceschi A, et al. Janus kinase inhibitors during pregnancy and adverse drug reactions: a pharmacovigilance disproportionality analysis in VigiBase. Clin Transl Sci. 2025;18(12):e70429. https:\/\/doi.org\/10.1111\/cts.70429.","DOI":"10.1111\/cts.70429"},{"issue":"1","key":"1263_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","volume":"26","author":"C Schaefer","year":"2008","unstructured":"Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod Toxicol. 2008;26(1):36\u201341.","journal-title":"Reprod Toxicol"},{"key":"1263_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.reprotox.2016.11.019","volume":"67","author":"E Beck","year":"2017","unstructured":"Beck E, Lechner A, Schaefer C. Who seeks teratology information Service\u2019s advice? Assessing the risk of selection bias in observational cohort studies on drug risks in pregnancy. Reprod Toxicol. 2017;67:79\u201384. https:\/\/doi.org\/10.1016\/j.reprotox.2016.11.019.","journal-title":"Reprod Toxicol"},{"issue":"2","key":"1263_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00228-017-2351-y","volume":"74","author":"K Dathe","year":"2018","unstructured":"Dathe K, Schaefer C. Drug safety in pregnancy: the German Embryotox institute. Eur J Clin Pharmacol. 2018;74(2):171\u201379. https:\/\/doi.org\/10.1007\/s00228-017-2351-y.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01263-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:13:43Z","timestamp":1792584823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01263-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01263-4","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"6 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Positive ethics approval was granted by the Ethics Committee of Charit\u00e9 \u2013 University Medical Center Berlin on January 9, 2026 (EA2\/288\/25). Research methods followed the principles of the Declaration of Helsinki. All patients and health care professionals were informed about data privacy, data collection and usage of their data, and they provide their consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"146"}}